BRAF and melanoma: Thus, thyroid carcinomas bearing BRAF mutations are less sensitive to BRAF inhibitors than melanomas and develop primary or acquired resistance due to additional mutations and activation of alternative signaling pathways that reinforce ERK signaling [63].